Bronolak 30 mg (20 tablets)
- $5.80
The instruction for medical use
of medicine
Bronolak
A trade name
Bronolak
Mezhdunarodnoye the unlicensed
name Ambroxol Dosage Form
of the Tablet of 30 mg
Structure
One tablet contains
active agent - Ambroxol (in the form of a hydrochloride) 30 mg,
auxiliary substances: corn starch, cellulose microcrystalline, K25 povidone, silicon dioxide colloidal, talc, magnesium stearate
Description
Round biconvex tablets of white or almost white color.
Pharmacotherapeutic group
Expectorant drugs. Mucolytics.
The code of automatic telephone exchange R05CB06
the Pharmacological
Pharmacokinetics At properties intake Ambroxol is completely soaked up from zheludochno – an intestinal path, the maximum concentration in blood plasma of 70 ng/ml is reached in 1 hour, linking with proteins of blood plasma makes 90%.
It is metabolized in a liver at the first passing approximately for 30%. Elimination half-life of drug from fabrics about 7 - 15 hours, from blood – 1 hour. Ambroxol is metabolized in a liver to inactive metabolites.
About 90% in the form of metabolites are removed generally with urine.
Ambroxol gets through a blood-brain barrier, through a placental barrier, is emitted with breast milk.
The effect of Ambroxol occurs in 2 hours after administration of drug and keeps within 9 – 10 hours.
A pharmacodynamics
Bronolak – mucolytic means. Active agent of drug – Ambroxol, is an active metabolite of Bromhexine. Possesses the significant expectorant action. Reduces viscosity of a phlegm due to increase in a serous component of a bronchial secret, activization of the hydrolyzing enzymes and lysosomes.
Ambroxol influences composition of bronchial secretion at the cellular level, by means of stimulation of synthesis of sulfomucin in scyphoid cells.
Bronolak stimulates synthesis and secretion of surfactant. Increases mukotsiliarny transport, facilitates removal of a phlegm from bronchial tubes.
Indications
- acute and chronic bronchitis
- pneumonia
- chronic obstructive pulmonary diseases
- bronchial asthma with difficulty of an otkhozhdeniye of a phlegm
- a bronchoectatic disease
Bronolak accept the Route of administration and doses inside after a meal, washing down with enough liquid.
To adults and children 12 years drug are more senior appoint 30 mg of a 2-3raz a day.
Duration of treatment is defined by the doctor individually and depends on the nature of a disease.
Without medical prescription 4-5dny is not recommended to take the drug more.
Side effects
Seldom
- diarrhea, dryness in a mouth, a constipation
- at prolonged use in high doses - a gastralgia, nausea, vomiting
- dryness of mucous membranes of airways, a rhinorrhea
- skin rash, a small tortoiseshell, a Quincke's disease
in some cases
- allergic contact dermatitis, an acute anaphylaxis
- weakness, a headache, a dysuria, a dieback.
Contraindications
- hypersensitivity to drug components
- the first trimester of pregnancy
- children's age up to 12 years
- the peptic ulcer of a stomach and duodenum
Medicinal interactions
leads Combined use with antibechic drugs to difficulty of an otkhozhdeniye of a phlegm against the background of reduction of cough.
Increases penetration into a bronchial secret of amoxicillin, a tsefuroksim, erythromycin and doxycycline.
Ambroxol is compatible to the drugs which are slowing down patrimonial activity.
The special
instructions Drug can influence a clinical picture in a peptic ulcer of a stomach and duodenum.
Pregnancy and the period of a lactation
With care to appoint drug in II and III trimester of pregnancy.
Ambroxol gets into breast milk therefore drug is not recommended
to be used in the period of a lactation, but at use in therapeutic doses of negative impact on the newborn is not revealed.
Features of influence of medicine on ability to run the vehicle or potentially dangerous to the mekhanizmamena affect ability to run the vehicle or potentially dangerous mechanisms.
Overdose
Symptoms: nausea, vomiting, diarrhea, dyspepsia.
Treatment: symptomatic therapy
the Form of release and packing
On 10 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On 2 packs together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions at a temperature not above 30 °C
to Store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
Without prescription
the Producer
the Owner of a trademark and the certificate of registration is the ROTAFARM company, Great Britain.
SEDIKO Pharmaceutical Co is made., First industrial zone, Six ov OktoberSiti, Egypt
SEDIKO Pharmaceutical Co. First Industrial Zone, 6th October City, Egypt).
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from the consumer on quality of products (goods)
of RK, Almaty, Suyunbaya 222 BTel St. / fax: 8 (7272) 529090
of medicine
Bronolak
A trade name
Bronolak
Mezhdunarodnoye the unlicensed
name Ambroxol Dosage Form
of the Tablet of 30 mg
Structure
One tablet contains
active agent - Ambroxol (in the form of a hydrochloride) 30 mg,
auxiliary substances: corn starch, cellulose microcrystalline, K25 povidone, silicon dioxide colloidal, talc, magnesium stearate
Description
Round biconvex tablets of white or almost white color.
Pharmacotherapeutic group
Expectorant drugs. Mucolytics.
The code of automatic telephone exchange R05CB06
the Pharmacological
Pharmacokinetics At properties intake Ambroxol is completely soaked up from zheludochno – an intestinal path, the maximum concentration in blood plasma of 70 ng/ml is reached in 1 hour, linking with proteins of blood plasma makes 90%.
It is metabolized in a liver at the first passing approximately for 30%. Elimination half-life of drug from fabrics about 7 - 15 hours, from blood – 1 hour. Ambroxol is metabolized in a liver to inactive metabolites.
About 90% in the form of metabolites are removed generally with urine.
Ambroxol gets through a blood-brain barrier, through a placental barrier, is emitted with breast milk.
The effect of Ambroxol occurs in 2 hours after administration of drug and keeps within 9 – 10 hours.
A pharmacodynamics
Bronolak – mucolytic means. Active agent of drug – Ambroxol, is an active metabolite of Bromhexine. Possesses the significant expectorant action. Reduces viscosity of a phlegm due to increase in a serous component of a bronchial secret, activization of the hydrolyzing enzymes and lysosomes.
Ambroxol influences composition of bronchial secretion at the cellular level, by means of stimulation of synthesis of sulfomucin in scyphoid cells.
Bronolak stimulates synthesis and secretion of surfactant. Increases mukotsiliarny transport, facilitates removal of a phlegm from bronchial tubes.
Indications
- acute and chronic bronchitis
- pneumonia
- chronic obstructive pulmonary diseases
- bronchial asthma with difficulty of an otkhozhdeniye of a phlegm
- a bronchoectatic disease
Bronolak accept the Route of administration and doses inside after a meal, washing down with enough liquid.
To adults and children 12 years drug are more senior appoint 30 mg of a 2-3raz a day.
Duration of treatment is defined by the doctor individually and depends on the nature of a disease.
Without medical prescription 4-5dny is not recommended to take the drug more.
Side effects
Seldom
- diarrhea, dryness in a mouth, a constipation
- at prolonged use in high doses - a gastralgia, nausea, vomiting
- dryness of mucous membranes of airways, a rhinorrhea
- skin rash, a small tortoiseshell, a Quincke's disease
in some cases
- allergic contact dermatitis, an acute anaphylaxis
- weakness, a headache, a dysuria, a dieback.
Contraindications
- hypersensitivity to drug components
- the first trimester of pregnancy
- children's age up to 12 years
- the peptic ulcer of a stomach and duodenum
Medicinal interactions
leads Combined use with antibechic drugs to difficulty of an otkhozhdeniye of a phlegm against the background of reduction of cough.
Increases penetration into a bronchial secret of amoxicillin, a tsefuroksim, erythromycin and doxycycline.
Ambroxol is compatible to the drugs which are slowing down patrimonial activity.
The special
instructions Drug can influence a clinical picture in a peptic ulcer of a stomach and duodenum.
Pregnancy and the period of a lactation
With care to appoint drug in II and III trimester of pregnancy.
Ambroxol gets into breast milk therefore drug is not recommended
to be used in the period of a lactation, but at use in therapeutic doses of negative impact on the newborn is not revealed.
Features of influence of medicine on ability to run the vehicle or potentially dangerous to the mekhanizmamena affect ability to run the vehicle or potentially dangerous mechanisms.
Overdose
Symptoms: nausea, vomiting, diarrhea, dyspepsia.
Treatment: symptomatic therapy
the Form of release and packing
On 10 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On 2 packs together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions at a temperature not above 30 °C
to Store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
Without prescription
the Producer
the Owner of a trademark and the certificate of registration is the ROTAFARM company, Great Britain.
SEDIKO Pharmaceutical Co is made., First industrial zone, Six ov OktoberSiti, Egypt
SEDIKO Pharmaceutical Co. First Industrial Zone, 6th October City, Egypt).
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from the consumer on quality of products (goods)
of RK, Almaty, Suyunbaya 222 BTel St. / fax: 8 (7272) 529090
Related Products
